Oral IgY antibodies neutralize pathogens and toxins at mucosal surfaces — without antibiotics, without resistance, and without disrupting the microbiome. A prevention‑first approach to chronic disease and infection.

OXIgYN delivers this capability in a field‑ready, chewable tablet format.

OXIgYN | Operational Readiness Platform
OXIgYN // GUT RESPONSE REGIMENT
CLASSIFIED: OPERATIONAL READINESS PLATFORM | STAGE 4
Field‑deployable chewable tablets

OXIgYN

Operational Readiness Platform
Protecting Personnel. Preserving Readiness. Reducing Operational Risk.
Oral (O) · Targeted (X) · IgY (Avian Antibodies) · Nutrition (N)

⚔️ PREVENT

Proactive force protection against gastrointestinal breakdown

🛡️ SUSTAIN

Nutrition + immune antibodies in a single field platform

🎯 RESTORE

Reduce inflammatory burden & microbiome disruption

OPERATIONAL THREAT ASSESSMENT

Gastrointestinal illness remains a silent readiness killer. Even in modern theaters, contaminated food, water, and operational stress impair gut integrity. Diarrhea, dehydration, fatigue, and cognitive decline rapidly degrade unit effectiveness.

>40%
deployed personnel affected annually (historical data)
2-5 DAYS
average duty limitation per episode
30%+
reduced physical performance during active illness

Consequences: mission interruption, medical evacuation, antibiotic pressure, secondary spread. OXIgYN addresses the vulnerability before it cripples readiness.

STRATEGIC VALUE & FORCE PRESERVATION

Military organizations invest in protective gear, vaccines, and water purification — but the gut remains an overlooked frontier. OXIgYN provides a dual‑action countermeasure that aligns with proactive health economics.

🔬 IMMUNE PROTECTION

Egg‑derived IgY antibodies target specific gastrointestinal pathogens & toxins directly inside the gut lumen — no systemic side effects, no microbiome devastation.

⚡ NUTRITIONAL SUSTAINMENT

Each chewable tablet delivers protein, dextrose energy, and micronutrients. A true protect + sustain platform for extended field operations.

“Prevention is cheaper than treatment.” Replacing reactive medical logistics with pre‑exposure gut defense reduces downstream costs: less IV fluids, fewer antibiotics, lower evacuation rates, and preserved combat power.

FIELD DEPLOYMENT SPECIFICATIONS
  • Chewable tablet – no water required
  • No cold chain / shelf‑stable
  • Lightweight & low logistical footprint
  • Integrates into MREs, deployment kits, survival packs
  • Scalable human‑grade manufacturing (cGMP)
  • Rapid onset of protective antibodies in the gut
▸ RATION COMPATIBLE ▸ HUMANITARIAN RESPONSE ▸ SPECIAL FORCES READY
BEYOND ACUTE INFECTION

Emerging science links microbiome disruption, endotoxemia (lipopolysaccharides), and chronic low‑grade inflammation to long‑term health and performance degradation. OXIgYN supports:

🌀 Gut barrier integrity
🌀 Post‑antibiotic recovery
🌀 Inflammatory balance (joints, brain, lungs)
🌀 Microbiome stabilization

This positions OXIgYN not only as a field countermeasure, but as a strategic asset for long‑duration deployments, naval operations, and remote garrisons.

OPERATIONAL APPLICATIONS
✓ Deployed military personnel ✓ Special operations support ✓ Naval & submarine deployments ✓ Disaster relief & humanitarian missions ✓ Northern/remote operations ✓ Long‑duration field exercises ✓ Emergency preparedness stockpiles ✓ Pandemic / outbreak response

“The true cost of gastrointestinal illness isn’t just a sick soldier — it’s a broken mission. Protecting the gut protects the force.”

— OXIgYN OPERATIONAL DOCTRINE
COST OF INACTION: HIDDEN BURDEN
  • Reduced combat effectiveness
  • Impaired decision-making & cognitive lag
  • Increased antibiotic consumption → resistance risk
  • Manpower rotation & replacement costs
  • Mission delays & intelligence gaps

OXIgYN offers a preemptive solution. Half an egg (20 tablets) per day fortifies gut immunity, reduces endotoxin load, and helps maintain battle rhythm.

TECHNOLOGY EDGE: MEGGABIOTICS™ PLATFORM

OXIgYN is built upon the MEGGABIOTICS™ oral antibody platform — hyperimmunized egg‑derived IgY technology, targeting pathogens directly. Unlike antibiotics, it preserves commensal flora and avoids resistance pressure.

✓ Phase 2 clinical history (C. difficile)
✓ Scalable biologics manufacturing
✓ Safe as food, effective as biologic

PROTECT THE GUT → PRESERVE THE MISSION → SUSTAIN THE FORCE
OXIgYN

Resetting human health from the gut out. A new category in operational gut defense — not a supplement, but a force multiplier.


⚙️ READY FOR SCALABLE INTEGRATION & MILITARY LOGISTICS

For operational data, supply integration, and field trial access: Contact the Joint Program Office.

Scroll to Top